Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
524.2 INR | +2.29% | +4.79% | +3.07% |
May. 29 | Jubilant Ingrevia Limited Receives A Show Cause Notice in DRC 01 from State Tax Officer, Bharuch | CI |
May. 14 | Transcript : Jubilant Ingrevia Limited, Q4 2024 Earnings Call, May 14, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.38 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.07% | 977M | B | ||
+21.29% | 68.19B | A- | ||
-1.79% | 48.31B | A- | ||
+25.03% | 44.85B | B+ | ||
+32.28% | 28.6B | A- | ||
+7.27% | 19.05B | C+ | ||
+11.50% | 16.53B | B+ | ||
-6.61% | 15.83B | B+ | ||
-20.33% | 15.49B | A- | ||
-21.16% | 13.41B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JUBLINGREA Stock
- Ratings Jubilant Ingrevia Limited